Prostate cancer tests

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 17:37, 11 December 2016 by PeterYang (talk | contribs) (Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' Is t...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there information missing from this list? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.


PSA

  • Increased PSA correlates with risk of prostate cancer and risk of aggressive prostate cancer, but does not mean that somebody has prostate cancer
  • May be transiently elevated due to:
    • Enlarged prostate, benign prostatic hypertrophy (BPH)
    • Infection (prostatitis)
    • Ejaculation/sexual activity
    • Digital rectal exam (DRE), prostate exam
    • Biopsies or other instrumentation

Free PSA

  • Free PSA helps to futher stratify likelihood of detecting prostate cancer [1]

ProPSA

PCA3

4kscore

PHI

MiPS

Promark

Apifny

MRI

Genetic/mutational screening

ConfirmDx

Oncotype DX Prostate

  • Oncotype DX Prostate Genomic Health's Genomic Prostate Score (GPS) & prognostic prostate cancer assay

Prolaris

  • Prolaris, Myriad's biomarker prognostic prostate cancer assay

Decipher

  • Decipher, GenomeDx's genomic prognostic prostate cancer assay
    • "the Decipher Test uses the expression of these biomarkers to calculate the probability of clinical metastasis within 5 years of radical prostatectomy surgery, and within 3 years of successive PSA rise (biochemical recurrence)."

References

  1. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998 May 20;279(19):1542-7. link to original article PubMed